In vivo microdialysis in Parkinson's Research

Journal of Neural Transmission, Supplementa

Volumn , Issue 73, 2009, Pages 223-243

  Di Giovanni, Giuseppe ^b   Esposito, Ennio ^a   Di Matteo, Vincenzo ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

6 OHDA; Basal ganglia; Free oxygen radicals.; Microdialysis; MPP+; MPTP; Parkinson's disease; ROS

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 5 HYDROXYINDOLEACETIC ACID; 7 NITROINDAZOLE; ADENOSINE A2A RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCITRIOL; DIMETHYLBENZ[A]ANTHRACENE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE DERIVATIVE; GLUTAMIC ACID; GLUTATHIONE; HYDROXYBENZOIC ACID; HYDROXYL RADICAL; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID; SUPEROXIDE DISMUTASE; DOPAMINE;

BASAL GANGLION; BRAIN CELL; CAUDATE NUCLEUS; CINGULATE GYRUS; CORPUS STRIATUM; EXTRACELLULAR FLUID; FRONTAL CORTEX; GLOBUS PALLIDUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; IN VIVO STUDY; MICRODIALYSIS; MOLECULAR PROBE; MOTOR CORTEX; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; REVIEW; SENSORIMOTOR CORTEX; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THALAMUS; ANIMAL; DISEASE MODEL; HUMAN; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; PATHOLOGY;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MICRODIALYSIS; PARKINSON DISEASE;

EID: 77952294415     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-92660-4-18     Document Type: Review

References (236)

1. Abarca J, Bustos G (1999) Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-D-aspartate receptors in rat striatum after partial and extensive lesions to the nigro-striatal dopamine pathway. Neurochem Int 35:19-33
2. Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525:36-44
3. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375
4. Alexander GE, Crutcher MD, De Long MR (1990) Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85:119-146
5. Amin AR, Vyas P, Attur M, Leszczynska-Piziak J, Patel IR, Weissmann G, Abramson SB (1995) The mode of action of aspirin-like drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA 92(17):7926-7930
6. Ampe B, Massie A, D'Haens J, Ebinger G, Michotte Y, Sarre S (2007) NMDA-mediated release of glutamate and GABA in the subthalamic nucleus is mediated by dopamine: an in vivo microdialysis study in rats. J Neurochem 103:1063-1074
7. Antonelli T, Fuxe K, Agnati L, Mazzoni E, Tanganelli S, Tomasini MC, Ferraro L (2006) Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. J Neurol Sci 248:16-22
8. Arai A, Kannari K, Shen H, Maeda T, Suda T, Matsunaga M (2003) Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. Brain Res 972:229-234
9. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2:325-334
10. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192
11. Benveniste H (1989) Brain microdialysis. J Neurochem 52:1667-1679
12. Bergquist F, Shahabi HN, Nissbrandt H (2003) Somatodendritic dopamine release in rat substantia nigra influences motor performance in the accelerating rod. Brain Res 973:81-91
13. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson's disease. Bioessays 24:308-318
14. Bianchi L, Galeffi F, Bolam JP, Della Corte L (2003) The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur J Neurosci 18:856-868
15. 2 receptors via the indirect striatal output pathway. Brain Res 753:163-175
16. Björklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R (2003) Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2:437-445
17. Blair RJ (2003) Facial expressions, their communicatory functions and neuro-cognitive substrates. Philos Trans R Soc Lond B Biol Sci 358:561-572
18. Blandini F, Nappi G, Tassorelli C, Martignoni E (2000) Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62:63-88
19. Blum D, Torch S, Lambeng N, Nissou M-F, Benabid A-L, Sadoul R, Verna J-M (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65:135-172
20. Bogdanov MB, Ferrante RJ, Mueller G, Ramos LE, Martinou JC, Beal MF (1999) Oxidative stress is attenuated in mice overexpressing BCL-2. Neurosci Lett 262:33-36
21. Booth RG, Castagnoli N Jr, Rollema H (1989) Intracerebral microdialysis studies of quinoline and isoquinoline derivatives related to MPTP/MPP+. Neurosci Lett 100:306-312
22. Bouchez G, Sensebé L, Vourc'h P, Garreau L, Bodard S, Rico A, Guilloteau D, Charbord P, Besnard JC, Chalon S (2008) Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int 52:1332-1342
23. Boulet S, Lacombe E, Carcenac C, Feuerstein C, Sgambato-Faure V, Poupard A, Savasta M (2006) Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J Neurosci 26:10768-10776
24. Bruet N, Windels F, Bertrand A, Feuerstein C, Poupard A, Savasta M (2001) High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. J Neuropathol Exp Neurol 60:15-24
25. Bruet N, Windels F, Carcenac C, Feuerstein C, Bertrand A, Poupard A, Savasta M (2003) Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats. J Neuropathol Exp Neurol 62:1228-1240
26. Buck K, Ferger B (2008) Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats. Neurobiol Dis 29:210-220
27. +). Neurosci Lett 117:129-133
28. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71:295-301
29. Castañeda E, Whishaw IQ, Robinson TE (1990) Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J Neurosci 10:1847-1854
30. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578
31. +. Free Radic Biol Med 13:581-583
32. Chiueh CC, Miyake H, Peng MT (1993) Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60:251-258
33. Chiueh CC, Wu RM, Mohanakumar KP, Sternberger LM, Krishna G, Obata T, Murphy DL (1994) In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann NY Acad Sci 738:25-36
34. Chiueh CC, Huang S-J, Murphy DL (1992b) Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11:346-348
35. 2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol 464:33-38
36. Cragg SJ, Nicholson C, Kume-Kick J, Tao L, Rice ME (2001) Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J Neurophysiol 85:1761-1771
37. Dawson TM (2000) New animal models for Parkinson's disease. Cell 101:115-118
38. De Long MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285
39. Dethy S, Laute MA, Damhaut P, Goldman S (1999) Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine. J Neural Transm 106:145-158
40. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-317
41. Di Giovanni G (ed) (2007) The basal ganglia pathophysiology: recent advances. Transworld research network, Trivandrum
42. Di Giovanni G (2008) Will it ever become possible to prevent dopaminergic neuronal degeneration? CNS Neurol Disord Drug Targets 7:28-44
43. Di Giovanni G, Di Matteo V, Esposito E (Eds) (2008) Serotonin-dopamine interaction: experimental evidence and therapeutic relevance. Prog Brain Res 172:ix
44. Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, Esposito E (2006a) Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res 1095:167-177
45. +-induced degeneration: an in vivo microdialysis study. Ann NY Acad Sci 1089:462-471
46. Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 15:1236-1239
47. Emborg ME (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods 139:121-143
48. Esposito E, Rotilio D, Di Matteo V, Di Giulio C, Cacchio M, Algeri S (2002) A review of specific antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 23:719-735
49. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007a) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205:295-312
50. Esposito E, Di Matteo V, Di Giovanni G (2007b) Death in the substantia nigra: a motor tragedy. Expert Rev Neurother 7:677-697
51. 2 and ATP production and on dopamine and DOPAC in the striatum. J Physiol Biochem 55:325-331
52. Fantin M, Auberson YP, Morari M (2008) Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striatopallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism. J Neurochem 106:957-968
53. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: SNc regional selectivity. Brain 114:2283-2301
54. Fedele E, Mazzone P, Stefani A, Bassi A, Ansaldo MA, Raiteri M, Altibrandi MG, Pierantozzi M, Giacomini P, Bernardi G, Stanzione P (2001a) Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids. Exp Neurol 167:356-365
55. Fedele E, Stefani A, Bassi A, Pepicelli O, Altibrandi MG, Frasca S, Giacomini P, Stanzione P, Mazzone P (2001b) Clinical and electrophysiological effects of apomorphine in Parkinson's disease are not paralleled by amino acid release changes: a microdialysis study. Funct Neurol 16:57-66
56. Ferger B, van Amsterdam C, Seyfried C, Kuschinsky K (1998) Effects of a-phenyl-tert-butylnitrone and selegiline on hydroxyl free radicals in rat striatum produced by local application of glutamate. J Neurochem 70:276-280
57. Ferger B, Teismann P, Mierau J (2000) The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res 883:216-223
58. Ferger B, Rose S, Jenner A, Halliwell B, Jenner P (2001a) 6-hydroxydopamine increases hydroxyl free radical production and DNA damage in rat striatum. Neuroreport 12:1155-1159
59. Ferger B, Themann C, Rose S, Halliwell B, Jenner P (2001b) 6-hydroxydopamine increases the hydroxylation and nitration of phenylalanine in vivo: implication of peroxynitrite formation. J Neurochem 78:509-514
60. Flaherty AW, Graybiel AM (1991) Corticostriatal transformations in the primate somatosensory system. Projections from physiologically mapped body-part representations. J Neurophysiol 66:1249-1263
61. +) mediates release of 1-3, 4-dihydroxyphenylalanine (L-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study. Chem Res Toxicol 16:1372-1384
62. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325
63. Galati S, Mazzone P, Fedele E, Pisani A, Peppe A, Pierantozzi M, Brusa L, Troppi D, Moschella V, Raiteri M, Stanzione P, Bernardi G, Stefani A (2006) Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease. Eur J Neurosci 11:2923-2928
64. Galeffi F, Bianchi L, Bolam JP, Della Corte L (2003) The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur J Neurosci 18:856-868
65. Gerhardt GA, Cass WA, Huettl P, Brock S, Zhang Z, Gash DM (1999) GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 817:163-171
66. Gerin C (2002) Behavioral improvement and dopamine release in a Parkinsonian rat model. Neurosci Lett 330:5-8
67. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595
68. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK (1994a) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. 1. Systemic administration. J Pharmacol Exp Ther 270:1000-1007
69. Giovanni A, Sonsalla PK, Heikkila RE (1994b) Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. 2. Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 270:1008-1014
70. Glinka Y, Gassen M, Youdim MBH (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm 50:55-66
71. Grondin R, Cass WA, Zhang Z, Stanford JA, Gash DM, Gerhardt GA (2003a) Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J Neurosci 23:1974-1980
72. Grondin R, Zhang Z, Ai Y, Gash DM, Gerhardt GA (2003b) Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog Drug Res 61:101-123
73. Grünewald T, Beal MF (1999) NOS knockouts and neuroprotection. Nat Med 5:1354-1355
74. Halliwell B, Kaur H (1997) Hydroxylation of salicylate and phenylalanine as assays for hydroxyl radicals: a cautionary note visited for the third time. Free Radic Res 27:239-244
75. Halliwell B, Kaur H, Ingelman-Sundberg M (1991) Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Radic Biol Med 10:439-441
76. Han J, Cheng FC, Yang Z, Dryhurst G (1999) Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J Neurochem 73:1683-1695
77. Höcht C, Opezzo JA, Taira CA (2007) Applicability of reverse microdialysis in pharmacological and toxicological studies. J Pharmacol Toxicol Methods 55:3-15
78. Hoffman AF, van Horne CG, Eken S, Hoffer BJ, Gerhardt GA (1997) In vivo microdialysis studies of somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF. Exp Neurol 147:130-141
79. Hornykiewicz O (1989) Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease-a critical analysis of the neurochemical evidence. Prog Neuropsychopharmacol Biol Psychiatry 13:319-328
80. Ishiwari K, Mingote S, Correa M, Trevitt JT, Carlson BB, Salamone JD (2004) The GABA uptake inhibitor beta-alanine reduces pilocarpine-induced tremor and increases extracellular GABA in substantia nigra pars reticulata as measured by microdialysis. J Neurosci Methods 140:39-46
81. Jellinger K (1989) Pathology of Parkinson's disease. In: Calne DB (ed) Handbook of experimental pharmacology. Springer, Berlin
82. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 (Suppl 3): S26-S38
83. Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 (Suppl): S82-S87
84. Jonkers N, Sarre S, Ebinger G, Michotte Y (2000) MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats. Eur J Pharmacol 407:281-291
85. Jonkers N, Sarre S, Ebinger G, Michotte Y (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 108:559-570
86. Jonkers N, Sarre S, Ebinger G, Michotte Y (2002) MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res 926:149-155
87. Kannari K, Tanaka H, Maeda T, Tomiyama M, Suda T, Matsunaga M (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J Neurochem 74:263-269
88. 1B receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346-1353
89. Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A (2002) Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 99:4708-4713
90. Kondoh T, Low WC (1994) Glutamate uptake blockade induces striatal dopamine release in 6-hydroxydopamine rats with intrastriatal grafts: evidence for host modulation of transplanted dopamine neurons. Exp Neurol 127:191-198
91. Lacombe E, Carcenac C, Boulet S, Feuerstein C, Bertrand A, Poupard A, Savasta M (2007) High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute L-3, 4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur J Neurosci 26:1670-1680
92. Langston JW, Ballard PA, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
93. Linazasoro G (2004) Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 19:743-754
94. Lindefors N, Ungerstedt U (1990) Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 115:248-252
95. Lindefors N, Brodin E, Tossman U, Segovia H, Ungerstedt U (1989) Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Exp Brain Res 74:527-534
96. Lindvall O, Hagell P (2000) Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 127:299-320
97. Liu M, Liu S, Peterson SL, Miyake M, Liu KJ (2002) On the application of 4-hydroxybenzoic acid as a trapping agent to study hydroxyl radical generation during cerebral ischemia and reperfusion. Mol Cell Biochem 234(235):379-385
98. Lotharius J, Dugan LL, O'Malley KL (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19:1284-1293
99. Maeda T, Kannari K, Suda T, Matsunaga M (1999) Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum. Brain Res 817:185-191
100. Mandel S, Grünblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17:729-762
101. Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L, Morari M (2000) Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats. Eur J Neurosci 12:1848-1850
102. Marti M, Mela F, Bianchi C, Beani L, Morari M (2002) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J Neurochem 83:635-644
103. Marti M, Mela F, Guerrini R, Calo G, Bianchi C, Morari M (2004a) Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 91:1501-1504
104. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M (2004b) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24:6659-6666
105. Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candelotti S, Simonato M, Cox BM, Morari M (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci 25:9591-9601
106. Marti M, Trapella C, Viaro R, Morari M (2007) The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. J Neurosci 27:1297-1307
107. + toxicity in substantia nigra: protection by desferrioxamine. Brain Res 773:76-81
108. +-induced neurotoxicity along with brain-derived neurotrophic factor induction. J Neurochem 76:351-360
109. + and β-carbolinium: a microdialysis study in rats. Neurosci Lett 302:65-68
110. Meissner W, Reum T, Paul G, Harnack D, Sohr R, Morgenstern R, Kupsch A (2001) Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. Neurosci Lett 303:165-168
111. Meissner W, Harnack D, Paul G, Reum T, Sohr R, Morgenstern R, Kupsch A (2002) Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. Neurosci Lett 328:105-108
112. Meissner W, Harnack D, Reese R, Paul G, Reum T, Ansorge M, Kusserow H, Winter C, Morgenstern R, Kupsch A (2003) High frequency stimulation of the subthalamic nucleus enhances striatal dopamine release and metabolism in rats. J Neurochem 85:601-609
113. Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 22:586-598
114. Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101:483-497
115. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88:1-16
116. Meyerson BA, Linderoth B, Karlsson H, Ungerstedt U (1990) Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients. Life Sci 46:301-308
117. Mignon LJ, Wolf WA (2005) 8-Hydroxy-2-(di-n-propylamino) tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 16:699-703
118. Miller DW, Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72:1516-1522
119. Mohanakumar KP, Muralikrishnan D, Thomas B (2000) Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- induced neurotoxicity. Brain Res 864:281-290
120. Montgomery J, Ste-Marie L, Boismenu D, Vachon L (1995) Hydroxylation of aromatic compounds as indices of hydroxyl radical production: a cautionary note revisited. Free Radic Biol Med 19:927-933
121. Morari M, O'Connor WT, Ungerstedt U, Bianchi C, Fuxe K (1996) Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat-II. Evidence for striatal N-methyl-D-aspartate receptor regulation of striatonigral GABAergic transmission and motor function. Neuroscience 72:89-97
122. Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci 36:2503-2508
123. Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE (1987) MPTP, MPP+ and mitochondrial function. Life Sci 40:721-729
124. Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T (2005) Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. J Neurosurg 103:968-973
125. Nomoto M, Fukuda T (1993) A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset. Neuropharmacology 32:473-477
126. Nowak P, Szczerbak G, Biedka I, Drosik M, Kostrzewa RM, Brus R (2006) Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in parkinsonian rats. In vivo microdialysis study. J Physiol Pharmacol 57:583-597
127. + in rat striatum. Brain Res 828:68-73
128. Obata T (1999b) Protective effect of imidaprilat, a new angiotensinconverting enzyme inhibitor against 1-methyl-4-phenylpyridinium ion-induced. OH generation in rat striatum. Eur J Pharmacol 378:39-45
129. Obata T (2002) Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping. Toxicol Lett 132:83-93
130. Obata T (2003) Phytic acid suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum. Brain Res 978:241-244
131. +-induced hydroxyl radical generation. J Neural Transm 113:1131-1144
132. +)-induced hydroxyl radical generation in the rat striatum. Eur J Pharmacol 539:34-38
133. +)-induced hydroxyl radical generation in rat striatum. Toxicology 218:75-79
134. +)-induced hydroxyl radical generation in rat striatum. Neurosci Res 54:192-196
135. Obata T (2006e) Tamoxifen protect against hydroxyl radical generation induced by phenelzine in rat striatum. Toxicology 222:46-52
136. +. J Neural Transm Gen-Sect 89:139-145
137. Obata T, Kubota S (2001) Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 308:87-90
138. +-induced hydroxyl radical in the rat striatum. Brain Res 860:166-169
139. +-induced hydroxyl radical generation via depolarization activated nitric oxide synthase in rat striatum. Brain Res 902:223-228
140. +) into the striatum is associated with hydroxyl free radical generation. Brain Res 906:170-175
141. +) - induced hydroxyl radical generation in rat striatum. Neurosci Lett 306:9-12
142. +) in rat striatum. Biochim Biophys Acta 1568:171-175
143. Obata T, Kinemuchi H, Aomine M (2002a) Protective effect of diltiazem, a L-type calcium channel antagonist, on bisphenol A-enhanced hydroxyl radical generation by 1-methyl-4-phenylpyridinium ion in rat striatum. Neurosci Lett 334:211-213
144. Obata T, Aomine M, Inada T, Kinemuchi H (2002b) Nicotine suppresses 1-methyl-4-phenylpyridinium ion-induced hydroxyl radical generation in rat striatum. Neurosci Lett 330:122-124
145. Obata T, Takahashi S, Kashiwagi Y, Kubota S (2008) Protective effect of captopril and enalaprilat, angiotensin-converting enzyme inhibitors, on paranonylphenol-induced. OH generation and dopamine efflux in rat striatum. Toxicology 250:96-99
146. Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL, Rodriguez-Diaz M (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62 (Suppl 1): S17-S30
147. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine- lesioned rats: a microdialysis study. Neuroscience 100:53-62
148. A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience 127:223-231
149. Ochi M, Shiozaki S, Kase H (2004b) L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease. Synapse 52:163-165
150. O'Connor WT (1998) Functional neuroanatomy of the basal ganglia as studied by dual-probe microdialysis. Nucl Med Biol 25:743-746
151. Opacka-Juffry J, Ashworth S, Hume SP, Martin D, Brooks DJ, Blunt SB (1995) GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Neuroreport 7:348-352
152. Opacka-Juffry J, Wilson AW, Blunt SB (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 810:27-33
153. Parent A (996) Carpenter's human neuroanatomy, 9th edn. Williams & Wilkins, Baltimore
154. Perese DA, Ulman J, Viola J, Ewing SE, Bankiewicz KS (1989) A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 494:285-293
155. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647
156. Rada P, Tucci S, Teneud L, Paez X, Perez J, Alba G, García Y, Sacchettoni S, del Corral J, Hernandez L (1999) Monitoring gamma-aminobutyric acid in human brain and plasma microdialysates using micellar electrokinetic chromatography and laser-induced fluorescence detection. J Chromatogr B Biomed Sci Appl 735:1-10
157. Ramassamy C (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545:51-64
158. Richard MG, Bennett JP Jr (1995) NMDA receptor blockade increases in vivo striatal dopamine synthesis and release in rats and mice with incomplete, dopamine-depleting, nigrostriatal lesions. J Neurochem 64:2080-2086
159. Riederer P, Gerlach M, Müller T, Reichmann H (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 13:466-479
160. Rioux L, Gaudin DP, Bui LK, Grégoire L, Di Paolo T, Bédard PJ (1991) Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience 40:123-131
161. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L (2004) Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 20:1255-1266
162. Robertson RG, Graham WC, Sambrook MA, Crossman AR (1991) Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Res 563:278-280
163. Robinson TE, Whishaw IQ (1988) Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res 450:209-224
164. Robinson S, Freeman P, Moore C, Touchon JC, Krentz L, Meshul CK (2003) Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp Neurol 180:74-87
165. Rocchitta G, Migheli R, Mura MP, Esposito G, Marchetti B, Desole MS, Miele E, Serra PA (2005) Role of endogenous melatonin in the oxidative homeostasis of the extracellular striatal compartment: a microdialysis study in PC12 cells in vitro and in the striatum of freely moving rats. J Pineal Res 39:409-418
166. Rocchitta G, Migheli R, Esposito G, Marchetti B, Desole MS, Miele E, Serra PA (2006) Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. J Pineal Res 40:204-213
167. Rodriguez M, Morales I, Gonzalez-Mora JL, Gomez I, Sabate M, Dopico JG, Rodriguez-Oroz MC, Obeso JA (2007) Different levodopa actions on the extracellular dopamine pools in the rat striatum. Synapse 61:61-71
168. Rodríguez-Gómez JA, Lu JQ, Velasco I, Rivera S, Zoghbi SS, Liow JS, Musachio JL, Chin FT, Toyama H, Seidel J, Green MV, Thanos PK, Ichise M, Pike VW, Innis RB, McKay RD (2007) Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells 25:918-928
169. + Eur. J Pharmacol 126:345-346
170. Rollema H, De Vries JB, Damsma G, Westerink BHC, Kranenborg GL, Kuhr WG, Horn AS (1988a) The use of in vivo dialysis of dopamine, acetylcholine, aminoacids and lactic acid in studies on the neurotoxin l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Toxicology 49:503-511
171. +-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J Pharmacol Exp Ther 245:858-866
172. + (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat and monkey striatum. Neurosci Lett 106:275-281
173. + analogues and related charged species. J Med Chem 33:2221-2230
174. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J Pharmacol Exp Ther 268:380-387
175. +-evoked hydroxyl radical formation but not dopamine efflux in rat striatum. J Neural Transm 106:477-486
176. Sachs C, Jonsson G (1975) Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 24:1-8
177. + neurotoxicity by N-methyl-D-aspartate antagonists. Brain Res 586:203-207
178. Santiago M, Granero L, Machado A, Cano J (1995) Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur J Pharmacol 280:251-256
179. + toxicity on striatal dopaminergic terminals. J Neurochem 68:732-738
180. + on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis. Brain Res 538:226-230
181. Santiago M, Westerink BHC, Rollema H (1991b) Responsiveness of striatal dopamine release in awake animals after chronic 1-methyl-4-phenylpyridinium ion-induced lesions of the substantia nigra. J Neurochem 56:1336-1342
182. Santiago M, Matarredona ER, Granero L, Cano J, Machado A (2000) Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals. Brain Res 858:26-32
183. Santiago M, Machado A, Cano J (2001) Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis. J Neurosci Methods 108:181-187
184. Sarre EG, Michotte Y (1996) Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists. Eur J Pharmacol 296:247-260
185. Sarre S, Yuan H, Jonkers N, Van Hemelrijck A, Ebinger G, Michotte Y (2004) In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 90:29-39
186. Sarre S, Lanza M, Makovec F, Artusi R, Caselli G, Michotte Y (2008) In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats. Eur J Pharmacol 584:297-305
187. Sauer H, Oertel WH (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59:401-415
188. Sayre ML, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172-188
189. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y (1989) Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 26:551-557
190. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108:1263-1282
191. Schober A (2004) Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318:215-224
192. Scholtissen B, Verhey FR, Steinbusch HW, Leentjens AF (2006) Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm 113:59-73
193. 2]-Met-enkephalinamide attenuates potassiumevoked GABA release after nigrostriatal lesion. J Neurochem 82:666-673
194. Serra PA, Esposito G, Enrico P, Mura MA, Migheli R, Delogu MR, Miele M, Desole MS, Grella G, Miele E (2000) Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease. Br J Pharmacol 130:937-945
195. Shen H, Kannari K, Yamato H, Arai A, Matsunaga M (2003) Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med 199:149-159
196. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550
197. Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11:151-167
198. Skirboll S, Wang J, Mefford I, Hsiao J, Bankiewicz KS (1990) In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp Neurol 110:187-193
199. Smith TS, Bennett JP Jr (1997) Mitochondrial toxins in models of neurodegenerative diseases. I: In vivo brain hydroxyl radical production during systemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions. Brain Res 765:183-188
200. +-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 5:2598-2600
201. Smith AD, Kozlowski DA, Bohn MC, Zigmond MJ (2005) Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp Neurol 193:420-426
202. Smith MP, Fletcher-Turner A, Yurek DM, Cass WA (2006) Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res 31:533-539
203. Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B, Wichmann T (2004) Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci 24:6417-6426
204. Staal RG, Sonsalla PK (2000) Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293:336-342
205. Stefani A, Fedele E, Galati S, Pepicelli O, Frasca S, Pierantozzi M, Peppe A, Brusa L, Orlacchio A, Hainsworth AH, Gattoni G, Stanzione P, Bernardi G, Raiteri M, Mazzone P (2005) Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. Ann Neurol 57:448-452
206. Stefani A, Fedele E, Galati S, Raiteri M, Pepicelli O, Brusa L, Pierantozzi M, Peppe A, Pisani A, Gattoni G, Hainsworth AH, Bernardi G, Stanzione P, Mazzone P (2006) Deep brain stimulation in Parkinson's disease patients: biochemical evidence. J Neural Transm Suppl 70:401-408
207. Ste-Marie L, Boismenu D, Vachon L, Montgomery J (1996) Evaluation of sodium 4-hydroxybenzoate as an hydroxyl radical trap using gas chromatography-mass spectrometry and high-performance liquid chromatography with electochemical detection. Anal Biochem 241:67-74
208. Strecker RE, Sharp T, Brundin P, Zetterström T, Ungerstedt U, Björklund A (1987) Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 22:169-178
209. + and MPP+. J Neural Transm 74:75-86
210. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631-634
211. 2 interactions in models of Parkinson's disease. Parkinsonism Relat Disord 10:273-280
212. Teismann P, Schwaninger M, Weih F, Ferger B (2001) Nuclear factorkappaB activation is not involved in a MPTP model of Parkinson's disease. Neuroreport 12:1049-1053
213. Themann C, Teismann P, Kuschinsky K, Ferger B (2001) Comparison of two independent aromatic hydroxylation assays in combination with intracerebral microdialysis to determine hydroxyl free radicals. J Neurosci Methods 108:57-64
214. Tisdall MM, Smith M (2006) Cerebral microdialysis: research technique or clinical tool. Br J Anaesth 97:18-25
215. Tossman U, Segovia J, Ungerstedt U (1986) Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopaminelesioned rats measured with microdialysis. Acta Physiol Scand 127:547-551
216. Touchon JC, Holmer HK, Moore C, McKee BL, Frederickson J, Meshul CK (2005) Apomorphine-induced alterations in striatal and substantia nigra pars reticulata glutamate following unilateral loss of striatal dopamine. Exp Neurol 193:131-140
217. Trevitt T, Carlson B, Correa M, Keene A, Morales M, Salamone JD (2002) Interactions between dopamine D1 receptors and gammaaminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies. Psychopharmacology 159:229-237
218. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central dopamine neurons. Eur J Pharmacol 5:107-110
219. Ungerstedt U (1991) Microdialysis-principles and applications for studies in animals and man. J Intern Med 230:365-373
220. von Bohlen und Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 73:151-177
221. Wachtel SR, Abercrombie ED (1994) L-3, 4-Dihydroxyphenylalanineinduced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamineoxidase A and B inhibitors. J Neurochem 63:108-117
222. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL (2006) Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases. Biochem Pharmacol 72:1197-1206
223. Wang S, Hu LF, Zhang Y, Sun T, Sun YH, Liu SY, Ding JH, Wu J, Hu G (2006) Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats. Neuropsychopharmacology 31:933-940
224. Wichmann T, De Long MR (2006) Neurotransmitters and disorders of the basal ganglia. In: Sieghel GeorgJ, Wayne AlbersR, Brady Scott T, Donald L (eds) Basic Neurochemistry: molecular, cellular and medical aspects, 7th edn. Elsevier, Boston
225. Windels F, Bruet N, Poupard A, Urbain N, Chouvet G, Feuerstein C, Savasta M (2000) Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur J Neurosci 12:4141-4146
226. Windels F, Carcenac C, Poupard A, Savasta M (2005) Pallidal origin of GABA release within the substantia nigra pars reticulate during high-frequency stimulation of the subthalamic nucleus. J Neurosci 25:5079-5086
227. + in vivo. Eur J Pharmacol 243:241-247
228. +-and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens. Life Sci 67:241-250
229. Yamamoto BK, Davy S (1992) Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 58:1736-1742
230. Yamato H, Kannari K, Shen H, Suda T, Matsunaga M (2001) Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport 12:1123-1126
231. Yang CS, Tsai PJ, Lin NN, Liu L, Kuo JS (1995) Elevated extracellular glutamate levels increased the formation of hydroxyl radical in the striatum of anesthetized rat. Free Radic Biol Med 19:453-459
232. Yang J, Hu LF, Liu X, Zhou F, Ding JH, Hu G (2006a) Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Life Sci 78:1940-1944
233. Yang YJ, Wang QM, Hu LF, Sun XL, Ding JH, Hu G (2006b) Iptakalim alleviated the increase of extracellular dopamine and glutamate induced by 1-methyl-4-phenylpyridinium ion in rat striatum. Neurosci Lett 404:187-190
234. You Z-B, Herrera-Marschitz M, Petterson E, Nylander I, Goiny M, Shou H-Z, Kehr J, Godukhin O, Hokfelt T, Terenius L, Ungerstedt U (1996) Modulation of neurotransmitter release by cholecystokinin in the neostriatum and substantia nigra of the rat: regional and receptor specificity. Neuroscience 74:793-804
235. Yuan H, Sarre S, Ebinger G, Michotte Y (2004) Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. Brain Res 1026:95-107
236. Zetterström T, Brundin P, Gage FH, Sharp T, Isacson O, Dunnett SB, Ungerstedt U, Björklund A (1986) In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 362:344-349